Latest News

TATVA

Tatva Chintan clarifies on recent volume increase; attributes it to market conditions.

Source |04:55 21 May 25

regulatory filings

Tatva Chintan Pharma Chem Limited responded to an inquiry from the National Stock Exchange of India (NSE) regarding a recent increase/spurt in the volume of its equity shares.
The company stated that it has been diligently disclosing all material events and information, including price-sensitive information, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Tatva Chintan clarified that it has not withheld any material information that could affect the price or volume of its shares.
The company believes the recent increase in share volume is purely due to prevailing market conditions and is market-driven.

TATVA

Tatva Chintan announces availability of Earnings Call recording

Source |13:48 05 May 25

results press release

Tatva Chintan Pharma Chem Limited has informed the exchanges that the recording of the Earnings Call held on Monday, 05 May 2025 at 05:00 p.m. IST is available on the company's website. The recording can be accessed via the link: https://www.tatvachintan.com//webfiles/FinancialInformation/Audio/0515202507150410031473.mp3. This information is also available on the company's website at www.tatvachintan.com.

TATVA

Tatva Chintan Q4 PAT down 89% YoY, FY25 PAT down 81%; Eyes over 25% topline growth in FY26

Source |09:29 05 May 25

results press release regulatory filings

Q4 FY25 Consolidated Financial Highlights (YoY):
- Revenue from Operations at ₹107.86 crore, up 9.77% from ₹98.27 crore in Q4 FY24.
- EBITDA (Excl. Other Income) at ₹8.95 crore, down 42.65% from ₹15.61 crore in Q4 FY24. EBITDA margin at 8.30% vs 15.88% in Q4 FY24.
- Profit After Tax (PAT) at ₹1.03 crore, down 89.29% from ₹9.61 crore in Q4 FY24. PAT margin at 0.95% vs 9.78% in Q4 FY24.
- Earnings Per Share (EPS) at ₹0.44 vs ₹4.11 in Q4 FY24.
FY25 Consolidated Financial Highlights (YoY):
- Revenue from Operations at ₹382.71 crore, down 2.74% from ₹393.50 crore in FY24.
- EBITDA (Excl. Other Income) at ₹34.21 crore, down 49.83% from ₹68.20 crore in FY24. EBITDA margin at 8.94% vs 17.33% in FY24.
- PAT at ₹5.71 crore, down 81.18% from ₹30.35 crore in FY24. PAT margin at 1.49% vs 7.71% in FY24.
- EPS at ₹2.44 vs ₹13.26 in FY24.
Operational Split (FY25 Revenue): PTC 32.8%, SDA 31.3%, Electrolyte Salts 1.6%, PASC 33.6%, Others 0.7%.
Chairman & MD's Comments (Mr. Chintan Shah):
- FY25 was marked by challenges including a tough macroeconomic environment, subdued demand, extended inventory destocking cycles, and geo-political developments impacting performance across segments.
- Despite external pressures, the company maintained its strategic course, deepening customer relationships, expanding product offerings, and investing in future capacities.
- Focus was on strengthening operational efficiency, investing in the future, and preparing the organization for the next phase of growth.
- Cautiously optimistic for the new financial year, with destocking trends and price falls gradually stabilising and clear signs of demand upticks visible.
- FY26 is poised to be a turnaround year with anticipated topline growth of over 25%.
- This expected growth, coupled with better operating leverage, is forecast to drive a meaningful improvement in EBITDA.
- Long-term structural growth drivers remain intact, and the company is committed to creating value for stakeholders.
- Sees the future as an opportunity to emerge stronger, leaner, and more aligned with evolving global customer needs.

TATVA

Tatva Chintan receives export order worth USD 3.55 million (₹ 29.95 crore)

Source |09:23 05 May 25

new orders press release

Tatva Chintan Pharma Chem Limited announced on 5 May 2025 the receipt of an export order valued at USD 35,55,000, which is equivalent to ₹ 29.95 crore (excluding tax).

The order is for the supply of Specialty Chemicals under the Pharma & Agro Intermediates & Speciality Chemicals (PASC) category.
The client is an international entity.
The company expects to deliver the order in November / December 2025, corresponding to the third quarter of the financial year 2025-26 (Q3 FY26).

TATVA

Tatva Chintan publishes Q4 and FY25 financial results extract

Source |09:19 03 May 25

results regulatory filings

Tatva Chintan Pharma Chem Limited announced the publication of the extract of its financial results for the quarter and financial year ended 31 March 2025.

The extract was published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on 03 May 2025.
The information is available on the company's website at www.tatvachintan.com.